Definitely agree that the market is blind.
At such a low valuation relative to existing revenue the market is not including the high potential of strong revenue growth related to the FDA approval of iTrack Advance, and especially not the potential of 2RT.
The original iTrack device released in 2008 has proved itself to be a highly desired device by leading surgeons, especially in the US. The original issue was efficiency and the difficulty of the procedure, and now iTrack Advance solves that, opening the potential market up to 50x more doctors! Clearly if doctors were willing to use this over alternatives when it was extremely difficult to use then it must have far superior efficacy and safety. Now that it is so much more efficient I definitely expect to see very high growth as new doctors rapidly take up the device. It helps as well that this device has some of the longest term safety and efficacy data
Nova Eye Medical (EYE) Discussion, page-601
-
- There are more pages in this discussion • 2,587 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.005(3.45%) |
Mkt cap ! $34.35M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.0¢ | 14.5¢ | $16.57K | 113.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 125700 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 64039 | 3 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |